Drug Combination Details
| General Information of the Combination (ID: C32605) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Dasatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | HER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | SRC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combinatorial therapy inhibited cellular growth, invasion and colonosphere formation and also reduced CSC population as evidenced by the decreased expression of CSC specific markers: CD133, CD44, CD166 and ALDH. | |||||
